Study name | Publication | Year | Phase | Blind | Stage | Sample size (n) | Treatment | ||
---|---|---|---|---|---|---|---|---|---|
Experiment | Control | Experiment | Control | ||||||
ASCEND-4 [12] | Lancet | 2017 | III | open-label | III, IV | 189,187 | Ceritinib 750 mg/day | Pemetrexed 500 mg/ m2 plus cisplatin 75 mg/m2 or carboplatin AUC 5–6 | |
NEJM, JCO | 2014, 2018 | III | open-label | III, IV, recurrent | 172,171 | Crizotinib 250 mg bid | Pemetrexed 500 mg/ m2 plus cisplatin 75 mg/m2 or carboplatin AUC 5–6 | ||
NEJM, Ann Oncol | 2017, 2020 | III | open-label | III, IV | 152,151 | Alectinib 600 mg bid | Crizotinib 250 mg bid | ||
NEJM, JCO | 2018, 2020 | III | open-label | III, IV | 137,138 | Brigatinib 180 mg/day after a 7-day lead-in period of 90 mg/day | Crizotinib 250 mg bid | ||
WCLC, JAMA Oncology | 2020, 2021 | III | open-label | III, IV | 143,147 | Ensartinib 225 mg qd | Crizotinib 250 mg bid | ||
Lancet, Lung cancer, ASCO | 2017, 2019, 2021 | III | open-label | IIIB, IV, recurrent | 103,104 | Alectinib 300 mg bid | Crizotinib 250 mg bid | ||
PROFILE 1029 [32] | JTO | 2018 | III | open-label | III, IV, recurrent | 104,103 | Crizotinib 250 mg bid | Pemetrexed 500 mg/ m2 plus cisplatin 75 mg/m2 or carboplatin AUC 5–6 | |
ALESIA [33] | Lancet Respir Med | 2019 | III | open-label | IIIB, IV | 125 62 | Alectinib 600 mg bid | Crizotinib 250 mg bid | |
CROWN [34] | NEJM | 2020 | III | open-label | III, IV | 149,147 | Lorlatinib 100 mg qd | Crizotinib 250 mg bid |